Abstract
Introduction:
Mitotane (o,p’–DD) is the drug of choice for Adrenocortical Carcinomas (ACC) and its measurement in plasma is essential to control drug administration.
Objective:
To develop and validate a simple, reliable and straightforward method for mitotane determination in plasma samples.
Method:
Drug-free plasma samples were collected in potassium-ethylenediamine tetraacetate (K-EDTA) tubes and spiked with 1.0, 2.5, 10.0, 25.0 and 50.0 µg/mL of mitotane (DDD). The p,p’-DDD was used as an Internal Standard (IS) and was added at 25.0 µg/mL concentration to all samples, standards and controls. Samples were submitted to protein precipitation with acetonitrile and then centrifuged. 50 uL of the supernatant was injected into an HPLC system coupled to a Diode Array Detector (DAD). DDD and IS were detected at 230 nm in a 12 min isocratic mode with a solvent mixture of 60 % acetonitrile and 40 % formic acid in water with 0.1 % pump mixed, at 0.6 mL/min flow rate, in a reversed-phase (C18) chromatographic column kept at 28°C. The sensitivity, selectivity, precision, presence of carry-over, recovery and matrix-effect, linearity, and method accuracy were evaluated.
Results:
The present study’s method resulted in a symmetrical peak shape and good baseline resolution for DDD (mitotane) and 4,4’-DDD (internal standard) with retention times of 6.0 min, 6.4 mim, respectively, with resolutions higher than 1.0. Endogenous plasma compounds did not interfere with the evaluated peaks when blank plasma and spiked plasma with standards were compared. Linearity was assessed over the range of 1.00 -50.00 µg/mL for mitotane (R2 > 0.9987 and a 97.80 %-105.50 % of extraction efficiency). Analytical sensitivity was 0.98 µg/mL. Functional sensitivity (LOQ) was 1.00 µg/L, intra-assay and inter-assay coefficient of variations were less than 9.98 %, and carry-over was not observed for this method. Recovery ranged from 98.00 % to 117.00 %, linearity ranged from 95.00 % to 119.00 %, and high accuracy of 89.40 % to 105.90 % with no matrix effects or interference was observed for mitotane measurements. Patients’ sample results were compared with previous measurements by the GC-MS method with a high correlation (r = 0.88 and bias = −10.20 %).
Conclusion:
DDD determination in plasma samples by the developed and validated method is simple, robust, efficient, and sensitive for therapeutic drug monitoring and dose management to achieve a therapeutic index of mitotane in patients with adrenocortical cancer.
Keywords:
Adrenocortical carcinoma; Mitotane; Liquid chromatography; Diode array; Analytical; Method validation; HPLC
HIGHLIGHTS
A simple and sensitive HPLC-DAD has been developed and validated for mitotone determination in plasma.
Plasma concentration of mitotane was assayed in adrenocortical cancer patients.
The assay is suitable for the therapeutic drug monitoring of mitotane in clinical settings.
Thumbnail
Thumbnail
Thumbnail
Thumbnail
